Perspective on sterile compounding practices and the draft guidelines
Tormo, V.J.
American Journal of Hospital Pharmacy 49(4): 946-947
1992
ISSN/ISBN: 0002-9289 PMID: 1595725 Document Number: 393218
Document emailed within 1 workday
Related Documents
Allen, L.V.; Okeke, C.C. 2007: Basics of compounding: the responsibilities of compounding personnel in implementing United States pharmacopeia chapter 797 pharmaceutical compounding-sterile preparations, part 2 International Journal of Pharmaceutical Compounding 11(4): 313-323Allen, L.V.; Okeke, C. 2007: Basics of compounding for the implementation of United States pharmaceopeia chapter 797 pharmaceutical compounding-sterile preparations, part 1 International Journal of Pharmaceutical Compounding 11(3): 230-236
Allen, L.V. 2019: Sterile Basics: Pharmaceutical Waters Used in Sterile and Nonsterile Compounding International Journal of Pharmaceutical Compounding 23(5): 399-402
Printz, C. 2012: Draft screening guidelines spark debate: possible drawbacks and long-term effects of new draft guidelines for prostate cancer screening Cancer 118(9): 2335-2336
Allen, L.V.; Okeke, C.C. 2008: Considerations for implementing United States pharmacopeia chapter 797 pharmaceutical compounding-sterile preparations, part 9: immediate use compounded sterile preparations International Journal of Pharmaceutical Compounding 12(5): 440-443
Cabaleiro, J.; Jackson, K. 2016: Root Cause Analysis, Part 2: STERILE COMPOUNDING International Journal of Pharmaceutical Compounding 20(2): 99-104
Akers, M.J. 2017: Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms International Journal of Pharmaceutical Compounding 21(1): 47-56
Yoch, D. 2017: U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies International journal of pharmaceutical compounding 21(2): 95-102
Allen, L.V. 2016: Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions International Journal of Pharmaceutical Compounding 20(5): 399-404
Gibbs, J.N.; Mazan, K.D. 2000: Compounding OTC Drugs: A Legal Perspective International Journal of Pharmaceutical Compounding 4(3): 180-181
Capps, S.; Jackson, R.A.; Winckler, S.C.; Tribble, P.; Anthony, C.J.; Halperin, J.A. 2000: The future of compounding: an industry perspective International Journal of Pharmaceutical Compounding 4(3): 204-205
1999: Personal information in medical research: excerpts from draft guidelines Bulletin of medical ethics No. 151: 9-11
1999: Personal information in medical research: excerpts from draft guidelines Bulletin of medical ethics No. 151: 9-11
Allen, L.V. 1997: General guidelines for the use of chemicals for prescription compounding International Journal of Pharmaceutical Compounding 1(1): 46
de Souza, H.Guedes.; Garcez, M.do.Carmo.; Pinheiro, V.A. 2009: Postscription: The Compounding Pharmacy in Brazil: A Pharmacist's Perspective International Journal of Pharmaceutical Compounding 13(1): 87-88
Orr, R.J.; Lacina, N.C.; Peters, L.S.; Flynn, G.L. 1978: Topical clindamycin for acne. Part 2: Guidelines for extemporaneous compounding American Pharmacy 18(12): 23-26
Morimoto, K.; Saitoh, M.; Hemmi, A.; Yamamoto, M.; Kaminuma, T. 1992: Preparation of the first draft of environmental health criteria for acetonitrile: production process of the draft Eisei Shikenjo Hokoku. Bulletin of National Institute of Hygienic Sciences 110: 73-77
Semple, C.A. 2001: Bases and spaces: resources on the web for accessing the draft human genome - II - after publication of the draft Genome Biology 2(6): Reviews 2001
Ema, M.; Fukui, Y.; Aoyama, H.; Fujiwara, M.; Fuji, J.; Inouye, M.; Iwase, T.; Kihara, T.; Oi, A.; Otani, H.; Shinomiya, M.; Sugioka, K.; Yamano, T.; Yamashita, K.H.; Tanimura, T. 2007: Comments from the Developmental Neurotoxicology Committee of the Japanese Teratology Society on the OECD Guideline for the Testing of Chemicals, Proposal for a New Guideline 426, Developmental Neurotoxicity Study, Draft Document (October 2006 version), and on the Draft Document of the Retrospective Performance Assessment of the Draft Test Guideline 426 on Developmental Neurotoxicity Congenital anomalies 47(2): 74-76
Pazdur, R. 2006: PROs: defining clinical benefit from the patient's perspective. Draft guidance provides direction in evaluating patient-reported outcomes Oncology 20(6): 660